Meta-Analysis 101 for Pathologists

As illustrated in this chapter, meta-analysis could be used more widely in anatomic pathology to integrate the results of multiple studies in a more precise manner than with currently used ad hoc summary tables. Experience with this methodology will hopefully persuade pathologists about the need to report data in a more consistent and explicit manner so that it could be readily extracted in the future by other investigators. Meta-analysis could also be used more often to estimate effect sizes across multiple studies in efforts at integrating the results from current studies with those previously published in the literature.

[1]  J. Crawford,et al.  Original research in pathology: judgment, or evidence-based medicine? , 2007, Laboratory Investigation.

[2]  Galvin,et al.  Page 2 Gupta R, Marchevsky AM, McKenna RJ, Wick M, Moran C, Zakowski MF, Suster S. Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med. 2008; 132(6): 926-30. , 2008 .

[3]  K. Kondo,et al.  WHO histologic classification is a prognostic indicator in thymoma. , 2004, The Annals of thoracic surgery.

[4]  A. Marx,et al.  New WHO histologic classification predicts prognosis of thymic epithelial tumors , 2002, Cancer.

[5]  S. K. Kim,et al.  Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. , 2004, The Annals of thoracic surgery.

[6]  A. Marchevsky,et al.  The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patients with lung cancer is not associated with decreased survival. , 2010, Human pathology.

[7]  S. Goodman,et al.  Have you ever meta-analysis you didn't like? , 1991, Annals of internal medicine.

[8]  M. Bracken,et al.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. , 2009, Journal of the National Cancer Institute.

[9]  Woo Ick Yang,et al.  Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. , 2005, Chest.

[10]  E. Ruffini,et al.  World Health Organization histologic classification: an independent prognostic factor in resected thymomas. , 2005, Lung cancer.

[11]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[12]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[13]  H. Matsuda,et al.  The World Health Organization histologic classification system reflects the oncologic behavior of thymoma , 2002, Cancer.

[14]  A. Marchevsky,et al.  The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung. , 2003, The Journal of thoracic and cardiovascular surgery.

[15]  F. Thivolet-Béjui,et al.  Correlation of the WHO Schema for the Classification of Thymic Epithelial Neoplasms With Prognosis: A Retrospective Study of 90 Tumors , 2002, The American journal of surgical pathology.

[16]  K. Dickersin.  The existence of publication bias and risk factors for its occurrence. , 1990, JAMA.

[17]  S. Suster,et al.  Evidence‐based pathology and the pathologic evaluation of thymomas , 2008, Cancer.

[18]  M. Jenicek,et al.  Meta-analysis in medicine. Where we are and where we want to go. , 1989, Journal of clinical epidemiology.

[19]  J. Ryś,et al.  Prognostic evaluation of cutaneous malignant melanoma: A clinicopathologic and immunohistochemical study , 1999, Journal of surgical oncology.

[20]  A. Marchevsky,et al.  World Health Organization classification of thymomas provides significant prognostic information for selected stage III patients: evidence from an international thymoma study group. , 2010, Human pathology.

[21]  S. Suster,et al.  Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. , 2008, Archives of pathology & laboratory medicine.

[22]  L. Akslen,et al.  Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Trevor J Pugh,et al.  Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients , 2007, BMC Cancer.

[24]  F. Rea,et al.  Long-term survival and prognostic factors in thymic epithelial tumours. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  K. Suda,et al.  Clinical usefulness of the WHO histological classification of thymoma. , 2005, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[26]  J. Nesland,et al.  Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome , 2001, The Journal of pathology.

[27]  K. Mai,et al.  Renal epithelioid angiomyolipoma: a study of six cases and a meta‐analytic study. Development of criteria for screening the entity with prognostic significance , 2009, Histopathology.

[28]  T. Camerini,et al.  Proposal of a novel system for the staging of thymic epithelial tumors. , 2005, The Annals of thoracic surgery.

[29]  J. Shrager,et al.  Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. , 2003, The Annals of thoracic surgery.

[30]  J. Wain,et al.  Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. , 2005, The Journal of thoracic and cardiovascular surgery.

[31]  Lawrence M. Weiss,et al.  Determining Tissue of Origin for Metastatic Cancers: Meta-analysis and Literature Review of Immunohistochemistry Performance , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[32]  SP Zodpey.  Meta-analysis in medicine. , 2003, Indian journal of dermatology, venereology and leprology.

[33]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[34]  Kenji Suzuki,et al.  Thymoma: a clinicopathologic study based on the new World Health Organization classification. , 2003, The Journal of thoracic and cardiovascular surgery.

[35]  A. Marchevsky,et al.  The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. , 2009, Human pathology.

[36]  F. Cappuzzo,et al.  Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[37]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[38]  K. Steinberg.  Cookbook medicine: recipe for disaster? , 2006, Journal of the American Medical Directors Association.

[39]  H. Müller-Hermelink,et al.  Thymoma and Thymic Carcinoma: An Update of the WHO Classification 2004 , 2005, Surgery Today.

[40]  F. Mosteller,et al.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.

[41]  A. Leppäniemi.  From Eminence-Based to Error-Based to Evidence-Based Surgery , 2008, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[42]  R. Penzel,et al.  Histologic classification of thymic epithelial tumors: Comparison of established classification schemes , 2002, International journal of cancer.